Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma

International Journal of Hematology

Volumn 70, Issue 3, 1999, Pages 163-168

  Iwasaki, Tsuyoshi ^a   Hamano, Teruaki ^a   Ogata, Atsushi ^a   Kakishita, Eizo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Bone marrow; Gene expression; Interleukin 6; Multiple myeloma

Indexed keywords

INTERLEUKIN 6; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; BONE MARROW CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MULTIPLE MYELOMA; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

BONE MARROW CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033210336     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Vernino L, McAnally LM, Ramberg J, Lipsky PE. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. J Immunol 1992;148:402-10.
2. Jelinek DF, Lipsky PE. The role of B cell proliferation in the generation of immunoglobulin secreting cells in man. J Immunol 1983;130:2597-604.
3. Gavarotti P, Baccadoro M, Redoglia V, Golzio F, Pileri A. Reactive plasmacytosis: case report and review of the literature. Acta Haematol 1985;73:108-10.
4. Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 1990;33:398-402.
5. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988;332:83-5.
6. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
7. Herrmann F, Andreef M, Gruss HJ, Brach MA, Lubbert M, Mertelsmann R. Interleukin-4 inhibits growth of multiple myeloma by suppressing interleukin-6 expression. Blood 1991;78:2070-4.
8. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989;73:1915-24.
9. Nilsson K, Jernberg H, Pettersson M. IL-6 as a growth factor for human myeloma cells. A short review. Curr Top Microbiol Immunol 1990;166:3-12.
10. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of IL-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-11.
11. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77:2794-5.
12. Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi TT. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 1994;86:391-3.
13. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
14. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987;17:1411-16.
15. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54.